Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study
- 17 October 2012
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 102 (3) , 193-202
Abstract
Background Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been associated with total and cardiovascular mortality in various clinical settings. Studies on its structural isomer, symmetric dimethylarginine (SDMA), are scarce. This study aimed to determine the associations of both ADMA and SDMA levels with secondary cardiovascular disease events and all-cause mortality in patients with stable coronary heart disease (CHD). Methods In the observational prospective cohort study KAROLA, 1,148 CHD patients were followed for a median of 8.1 years. ADMA and SDMA were determined by liquid chromatography–tandem mass spectrometry. Baseline ADMA and SDMA levels were categorized in quartiles or standardized by their respective standard deviation, and appropriate hazard ratios and 95 % confidence intervals (HR [95 % CI]) were estimated in Cox proportional hazards models. Results 150 patients experienced secondary cardiovascular disease events (CVD) and 121 patients died. After adjustment for confounders, ADMA was not associated with the risk of secondary CVD events (HR per standard deviation increase: 1.02 [95 %CI: 0.86–1.21]), whereas an association was suggested for SDMA (HR 1.17 [1.00–1.37]). Higher hazard ratios were observed in all-cause mortality models (ADMA: HR 1.15 [0.95–1.37]; SDMA: HR 1.29 [1.09–1.52]). Conclusions Our results suggest that especially SDMA might possibly have potential as a risk marker for all-cause mortality and to a lesser extent for secondary cardiovascular events. Future studies are needed to quantify these associations more precisely and should, in particular, further address the possibility of residual confounding by impaired kidney function.Keywords
This publication has 35 references indexed in Scilit:
- Prognostic value of chronic kidney disease in patients with coronary heart disease: Role of estimating equationsAtherosclerosis, 2010
- Dimethylarginine Dimethylaminohydrolase Overexpression Ameliorates Atherosclerosis in Apolipoprotein E-Deficient Mice by Lowering Asymmetric DimethylarginineThe American Journal of Pathology, 2010
- Dose‐response analyses using restricted cubic spline functions in public health researchStatistics in Medicine, 2010
- Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular RisksArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Association of the Endogenous Nitric Oxide Synthase Inhibitor ADMA With Carotid Artery Intimal Media Thickness in the Framingham Heart Study Offspring CohortStroke, 2009
- Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the CommunityCirculation, 2009
- New Predictive Equations Improve Monitoring of Kidney Function in Patients With DiabetesDiabetes Care, 2007
- Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) studyAmerican Heart Journal, 2006
- Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortalityClinical Chemistry and Laboratory Medicine (CCLM), 2005
- Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in ratsBiochemical and Biophysical Research Communications, 1987